News for Chugai Pharmaceutical Co., Ltd. (CHGCF)

**media[558065]**

Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC; Announcement of initial data from 12-month evaluable patients expecte

New data on Nemluvio® (nemolizumab), including an oral e-poster presentation characterizing the impact of Nemluvio in different pruriginous lesion types in prurigo …

https://mms.businesswire.com/media/20250213843444/en/2382130/19/GALDERMA_BERLIN_2025_INTERVIEW_YOUTUBE_V4.mp4 Ad hoc announcement pursuant to Art. 53 LR

Chugai Pharmaceutical Co., Ltd. (OTCPK:CHGCF) Q4 2024 Earnings Conference Call January 30, 2025 3:30 AM ETCompany ParticipantsKae Miyata - Head of Corporate...

The following slide deck was published by Chugai Pharmaceutical Co., Ltd.

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O N4519.T - Chugai Pharmaceutical Co LtdFull Year 2024 Chugai Pharmaceutical Co Ltd Earnings Pres

Japan stocks lower at close of trade; Nikkei 225 down 0.87%

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Galderma Receives U.S. FDA Approval for Nemluvio ® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis

Ad hoc announcement pursuant to Art. 53 LR

Atopic dermatitis is a common, chronic, and flaring inflammatory skin disease characterized by persistent itch and recurrent skin lesions, and affects approximately…

CHMP Recommends Approval of Galderma's Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union

TARA-002 demonstrates 72% six-month landmark complete response rate and 70% complete response rate at any time across BCG exposures100% six-month landmark compl

NEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. ( TARA), a clinical-stage company developing transformative therapies for the treatment

https://mms.businesswire.com/media/20241127699136/en/2313760/19/JAMA_PR_MM_Asset.mp4 Full results from the phase III OLYMPIA 1 trial evaluating the efficacy an…

Japan stocks lower at close of trade; Nikkei 225 down 1.05%

Japan stocks higher at close of trade; Nikkei 225 up 1.16%

Japan stocks higher at close of trade; Nikkei 225 up 0.60%